insitro
Insitro is a drug discovery company that applies machine learning to biology, using its TherML™ platform to design new therapeutics.
Secondary Market Price
How insitro Measures Up
To help you manage your insitro equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series C
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of insitro's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future insitro Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for insitro's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Insitro is a drug discovery and development company that applies machine learning to large-scale biological and genetic datasets. The company’s platform integrates human and cellular data to identify disease mechanisms, prioritize drug targets, and design potential medicines, with a focus on metabolic diseases and neuroscience, including programs in ALS, MASH, and dry AMD. Founded in 2018 by Daphne Koller, insitro was established to build an AI-enabled causal biology engine to make the drug discovery process more scalable and predictable.
Looking forward, insitro expects its first therapeutic program to enter clinical trials in 2024. The company recently announced the acquisition of CombinAbleAI and the launch of TherML™, a unified therapeutic design platform that works across small molecules, oligonucleotides, and complex biologics. This acquisition also led to the establishment of a new R&D center in Israel. Other recent developments include the publication of its CellPaint-POSH platform, which uses machine learning for large-scale gene function mapping, and the appointment of new leadership to its small molecule drug discovery team.
- Andreessen Horowitz
- ARCH Venture Partners
- Foresite Capital
- GV
- Third Rock Ventures
- Two Sigma Ventures
- Alexandria Venture Investments
- Canada Pension Plan Investment Board
- T. Rowe Price Associates
- BlackRock
- Casdin Capital
- HOF Capital
- WuXi AppTec's Corporate Venture Fund
- Temasek
- SoftBank Investment Advisors
- Co-Founder, CEO Daphne Koller
- Co-Founder, Vijay Pande
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is insitro worth joining?
Deciding if a pre-IPO company like insitro is worth joining depends on your personal career goals and risk tolerance. Tools can help you evaluate the potential financial upside of your equity offer by forecasting its future value.
What should I do with my insitro stock?
Managing stock in a private company like insitro involves complex tax and financial planning to maximize your returns. Platforms like Prospect provide customized, data-driven strategies for exercising options and selling shares at the optimal time.
Can you sell insitro stock?
Selling stock in a private company like insitro is typically possible through secondary markets or company-led tender offers, though restrictions often apply. Equity management platforms can help you identify selling opportunities and determine which shares are the most tax-optimal to sell.
How can I find the value of my insitro stock?
Valuing stock in a private company is difficult because it doesn't trade on a public market, but you can look at the company's 409A valuation or recent funding rounds. To get a more sophisticated analysis, Prospect uses machine learning models to project a range of likely outcomes for your equity's value.
What is insitro's equity worth?
The exact worth of private equity like insitro's isn't public information and fluctuates based on company performance and market conditions. Financial tools can help you forecast a range of potential values based on data from funding rounds, secondary markets, and other growth indicators.
What is insitro's stock ticker symbol?
As a private, pre-IPO company, insitro does not have a stock ticker symbol because its shares are not traded on a public stock exchange. A ticker symbol will only be assigned if and when the company decides to go public through an Initial Public Offering (IPO).
Can I buy or sell insitro stock?
Selling stock in a private company is sometimes possible through secondary markets, while buying shares is typically restricted to employees or accredited investors. Tools exist to help employees manage and sell their existing equity, but they are not platforms for purchasing new shares.
What is the criteria to buy or invest in insitro stock?
Investing in a private company like insitro is generally limited to accredited investors participating in funding rounds or employees who receive equity as part of their compensation. Unlike public companies, you cannot simply buy shares through a standard brokerage account.
